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Malignant Mesothelioma (MM) is a rare and highly aggressive cancer that develops from
mesothelial cells lining the pleura and other internal cavities, and is often associated
with asbestos exposure. To date, no effective treatments have been made available
for this pathology. Herein, we propose a novel immunotherapeutic approach based on
a unique vaccine targeting a series of antigens that we found expressed in different
MM tumors, but largely undetectable in normal tissues. This vaccine, that we term
p-Tvax, is comprised of a series of immunogenic peptides presented by both MHC-I
and -II to generate robust immune responses. The peptides were designed using in
silico algorithms that discriminate between highly immunogenic T cell epitopes and
other harmful epitopes, such as suppressive regulatory T cell epitopes and autoimmune
epitopes. Vaccination of mice with p-Tvax led to antigen-specific immune responses that
involved both CD8+ and CD4+ T cells, which exhibited cytolytic activity against MM cells
in vitro. In mice carrying MM tumors, p-Tvax increased tumor infiltration of CD4+ T cells.
Moreover, combining p-Tvax with an OX40 agonist led to decreased tumor growth and
increased survival. Mice treated with this combination immunotherapy displayed higher
numbers of tumor-infiltrating CD8+ and CD4+ T cells and reduced T regulatory cells in
tumors. Collectively, these data suggest that the combination of p-Tvax with an OX40
agonist could be an effective strategy for MM treatment.
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INTRODUCTION
Malignant Mesothelioma (MM) is a rare but highly aggressive
cancer that develops from mesothelial cells lining the pleura
and other internal cavities and is often associated with asbestos
exposure. To date, no effective treatments are available for
MM (1). Over the past decade, immunotherapeutic approaches
have created new opportunities to efficiently combat cancer
progression. The introduction of CAR T-cell therapies as well
as the successful use of antibody-based inhibitors of immune
checkpoints (e.g., Cytotoxic T Lymphocyte Associated protein
4, CTLA-4; Programmed cell Dead protein 1, PD-1; and its
ligand PD-L1) have invigorated the field of immunotherapy
and benefited an increasing number of cancer patients (2).
Anti-tumor therapy using personalized vaccines individually
tailored for immune responses against the patient’s mutanome
have been demonstrated to improve the therapeutic outcome
of biologics (3, 4). This approach, however, includes limitations
such as potential delays between biopsy, design and production
of the vaccine, in addition to high costs for vaccine production.
Moreover, MM vaccines containing epitopes that are common
to MM may be used as a means to prevent tumor development,
for individuals exposed to asbestos and in regions of the world
whereMM risk is high. MM requires up to 40 years from the time
of asbestos exposure to the development of disease, therefore,
it is conceivable that preventive vaccination approaches such as
the one currently used for HPV-associated cervical cancer might
similarly reduce MM incidence.
Herein, we describe the development of a novel
immunotherapeutic approach based on a unique vaccine
that targets a series of self-antigens that we found to be
commonly over-expressed in different MM mouse tumors
compared to normal tissues. Efficacious treatment using this
vaccine is demonstrated in three different MM animal models,
suggesting this approach may be used as a model to develop an
off-the-shelf immunotherapy for human patients that overcomes
some of the limitations of personalized anti-cancer vaccines
described above. Our vaccine, named p-Tvax, is comprised of
a series of immunogenic peptides containing both MHC-I and
-II restricted T cell epitopes and derived from multiple MM
antigens. The antigens included in the vaccine were chosen
based on their high expression in MM tumor tissues and low
levels in normal tissues in an attempt to minimize the risk
of triggering immune responses against healthy tissues. Each
peptide was designed using the iVAX platform comprising of
state-of-the-art in silico algorithms including EpiMatrix and
JanusMatrix, which have been previously demonstrated as
effective tools to discriminate between highly immunogenic T
cell epitopes and other undesirable epitopes such as suppressive
regulatory T cell epitopes (Tregitopes) or autoimmune epitopes
(autoepitopes) (5–7). JanusMatrix’s ability to identify tumor
epitopes cross-conserved with autoepitopes is particularly
relevant for designing new cancer immunotherapies, as
exemplified by previous therapies failing due to off-target cardiac
or neurologic toxicities (8, 9).
Even if peptide-based vaccines are found to activate
anti-cancer T cells, the efficacy of these immune cells is
mitigated within the tumor microenvironment by several
mechanisms. Many of these suppressive mechanisms are driven
by immunological checkpoint molecules such as PD-1 and
CTLA-4, or by immune co-stimulatory proteins such as OX40.
To overcome these suppressive mechanisms and generate
effective anti-tumor immune responses, we have combined p-
Tvax with an OX40 agonist. OX40 is a Tumor Necrosis Factor
receptor family member that is expressed by both activated T
effector cells and Foxp3+ T regulatory cells (Tregs). Ligands
that promote OX40 signaling, as well as agonistic monoclonal
antibodies (mAbs) that target this molecule, induce the activation
and proliferation of effector T cells, while reducing Treg activity
through the inhibition of Foxp3 gene expression (10–12).
Humanized versions of OX40 agonists have been positively
evaluated in a phase I clinical trial, and are now under
investigation in phase II (13). In this study, we present results
of this dual therapeutic approach that support the concept that a
universal cancer vaccine for MMmay offer a safe and potentially
curative therapy for this deadly cancer when combined with
mAbs that target T cell co-stimulation.
MATERIALS AND METHODS
Mice and Cells
Female 6–8 week-old BALB/c mice were obtained from the
Jackson Laboratory. Animal experiments were performed in
accordance with institutional guidelines and approved by the
University of Hawaii IACUC (#16-2355). Murine AB12MM cells
derived from asbestos-induced tumors in a BALB/c mouse were
provided by Dr. B. Robinson (University of Western Australia,
Nedlands, Australia) (14). Murine CRH5 and EOH6MM cells
were isolated from peritoneal ascites developed in asbestos-
or erionite-injected mice in carcinogenesis experiments as
previously described (15). Mesothelial cells were isolated as
previously described from naive BALB/c mice (16). All cells were
cultured in Ham’s F12 medium (Corning) containing 10% fetal
bovine serum (FBS) and antibiotics. All MM cells used in this
study were provided to our laboratories or purchased between
2004 and 2007.
Transcriptome Microarray Analysis
BALB/c mice were injected subcutaneously (s.c.) with 105 of
either CRH5 or EOH6MM cells. When tumors reached 100
mm3 they were excised and total RNA was extracted. At
the same time, RNA was isolated from lungs and kidneys
excised from naïve BALB/c mice. RNA expression in the
different tissues was evaluated using the Clariom S Mouse
Array (Affymetrix). Expression values were normalized and
summarized into transcript clusters for analysis using Robust
Multi-array Average approach in Array Studio (OmicSoft, Cary,
NC). One-way ANOVA was used to look for differential
expression between normal and tumor samples, and p-values
were adjusted for multiple comparisons using the Benjamini-
Hochberg False Discovery Rate (FDR) method. Only candidates
with FDR-adjusted p< 0.001 were considered. The data gathered
from this analysis were deposited in the Gene Expression
Omnibus (GEO) database (Accession Number: GSE122004).
Frontiers in Oncology | www.frontiersin.org 2 August 2019 | Volume 9 | Article 720
Hoffmann et al. Multi-antigen Vaccination for Mesothelioma Treatment
Western Blot Analysis
Frozen tumors and normal tissues were lysed in ice-cold buffer
containing 150mM NaCl, 50mM Tris, 1% Triton X-100, 1%
sodium deoxycholate, and protease inhibitor cocktail (Roche
Applied) at 4◦C for 1 h. Insoluble material was removed by
centrifugation at maximum speed for 5min, and total protein in
the supernatant was determined using a Bradford assay reagent
(Bio-Rad). After adjusting to equal protein concentration, lysates
were boiled in SDS sample buffer and then separated by SDS-
PAGE, followed by transfer of the proteins onto nitrocellulose
membranes. Blots were incubated with primary anti-TROAP
(Clone 3-11, Novus Biological), anti-OLFML2B (Mybiosurce),
anti-KIF20A (Clone D-3 Santa Cruz), or anti-β-actin (Sigma)
for 1.5 h, washed, incubated with appropriate HRP-conjugated
secondary antibody (1:20,000; Li-Cor), and visualized using the
Odyssey Scanner (Li-Cor).
Epitope Selection and Peptide Synthesis
Antigens selected after the transcriptomic analysis were screened
for BALB/c MHC-I (H2-Dd, H2-Kd) and MHC-II (H2-IAd, H2-
IEd) restricted T cell epitopes using the EpiMatrix algorithm. In
addition, putative Tregitopes and autoepitopes were identified
using the JanusMatrix algorithm (6). Briefly, each protein
sequence was first parsed into overlapping 9-mer frames. Each
frame was then evaluated with EpiMatrix and JanusMatrix to
determine its likelihood of binding to MHC-I (H2-Dd, H2-
Kd) and MHC-II (H2-IAd, H2-IEd) alleles and its potential
to induce Tregs, respectively. One peptide sequence enriched
in MHC-I and -II epitopes and devoid of putative Tregitopes
was derived from each selected antigen. Synthetic peptides were
manufactured by twenty-first century Biochemicals (Marlboro,
MA) using fluorenylmethoxycarbonyl chemistry and solid-phase
synthesis and purified by high-pressure liquid chromatography.
The quality of the peptides was assessed by high-performance
liquid chromatography analysis. Peptide purity was >90% as
ascertained by analytical reversed phase HPLC. Individual
peptides were dissolved with 10 µl DMSO, diluted to 1 mg/ml
with PBS and used at a final concentration of 10µg/ml in
ex vivo assays (DMSO 0.001%). A mixture of all peptides (10
µg/peptide), which we termed p-Tvax, was used to vaccinatemice
in 100 µl PBS.
Immunotherapies Schedule and Flow
Cytometric Analysis for Intracellular IFN-γ
BALB/c mice were vaccinated with two s.c. injections of p-Tvax
peptides (10 µg of each of the seven peptides, diluted in PBS), 1
week apart (day 2 and day 9). Two days before each vaccination,
50 µg CpG ODN 1585 adjuvant (Invitrogen) was injected at
day 0 and day 7, while 200 µg of OX40 agonists (clone OX86,
kindly provided by Dr. A. Weinberg) were injected at day 4
and day 9. Five days after the last vaccination, spleens were
excised from controls, and from mice treated with the different
immunotherapies. One million cells were stimulated for 24 h
with 10µg/ml of each p-Tvax peptides. For detection of IFN-γ
in the cytoplasm, Brefeldin A was added 6 h before staining.
Fixation/permeabilization kits were used in combination with
the following fluorochrome conjugated monoclonal antibodies:
Anti-CD3-PerCP/Cy5.5 (clone OKT3), anti-CD4-AlexaFluor700
(clone RM4-5), anti-CD8-APC/Cy7 (clone 53-6.7), and IFN-γ-
FITC (clone XMG1.2) antibodies. Live cells were distinguished
from debris using Aqua LIVE/DEAD R© cell viability dye (all
from Biolegend). Cells were evaluated using LSRFortessa Flow
Cytometer (BD Biosciences) and the data were analyzed with
FlowJo software.
Granzyme B ELISpot Assay
To measure T cell cytotoxicity, granzyme B secretion was
analyzed using the Mouse Granzyme B ELISpot Kit (R&D
system). Splenocytes were cultured with each single p-Tvax
peptide for 6 d, with peptides replenished every 2 d. At
day 3, cultures were supplemented with 5 IU/ml IL-2. At
day 6, splenocytes stimulated with the different peptides were
pooled together and dead cells removed with Lympholyte M
(Cedarlane). Splenocytes not stimulated with the peptides were
processed similarly. Stimulated and control splenocytes (104
effector cells) were then co-cultured with different MM cells (5
× 103 target cells) or with mesothelial cells in 200 µL media.
Negative controls consisted of effector cells in the absence of
target cells, target cells in the absence of effector cells and
media only. After 4 h of incubation, detection of granzyme B
spots was performed following the manufacturer’s directions.
Spots were then analyzed and counted with an ImmunoSpot
analyzer (CTL), with the instrument sensitivity kept low to
reduce background.
Murine Therapeutic Experiments
To evaluate the efficacy of the different immunotherapies on
tumor dimensions and mouse survival, s.c., and intraperitoneal
(i.p.) mouse models of MM were employed. In the s.c. model,
5 × 104 CRH5 cells were injected in the hind flank in cohorts
of five BALB/c mice. When tumors became palpable on day
7 (3–4mm in maximal diameter), mice were vaccinated as
described above. Tumor size was measured weekly using digital
calipers until the first death was recorded. Survival was then
followed until tumors reached volumes >300 mm3. For the
i.p. model of MM, 2 × 105 EOH6 cells or 5 × 104 AB12
cells were injected i.p. in cohorts of 5 BALB/c mice. Both
MM cells were previously transduced with the lentiviral vector
hPGK.lu2.WPRE.mhCMV.dNGFR.SV40PA, which encoded the
bioluminescent genetic marker luciferase (provided by Dr.
Naldini, San Raffaele University and Research Institute, Milano,
Italy). Immunotherapies were performed as scheduled for the
s.c. model. To assess tumor dimension and localization of
luminescent cells, mice were injected i.p. with 15 mg/ml d-
luciferin, bioluminescence signals of MM inoculated mice were
monitored using the IVIS system (PerkinElmer). Regions of
interest were identified around the tumor sites and were
quantified as total photon counts using Living Image software
(PerkinElmer). For survival, animals were monitored weekly
and euthanized when they appeared moribund according to
IACUC guidelines.
Isolation and Analysis of Tumor-Infiltrating
Immune Cells
CRH5 or EOH6MM cells were injected s.c. in cohorts of
five BALB/c mice. When tumors reached 50mm in maximal
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diameter, mice received the same immunotherapies regimens
indicated above. Five days after the last vaccination, tumors
were excised, washed with PBS, minced and incubated for 1 h
at 37◦C in digestion buffer consisting of 1 mg/ml collagenase
IV, 100 µl/ml hyalurodinase and 15 mg/ml DNAse I (all from
Roche Applied Sciences) in PBS. After digestion, tumors were
forced through a 40µm cell strainer. A total of 106 cells
were stained for flow cytometer analysis to characterize tumor-
infiltrating T lymphocytes. The same fluorochrome conjugated
monoclonal antibodies used for the analysis of T cell responses
were utilized plus anti-CD25-PE/Cy7 clone PC61 and anti-
FoxP3-FITC clone MF-14 for Tregs analysis, or plus anti-PD-
1-PE/Cy7 clone RMP1-30 and anti-OX40-PE clone OX86 for T
cell marker analysis (all from Biolegend). Cells were analyzed
using LSRFortessa Flow Cytometer (BD Biosciences) and data
organized with FlowJo software.
Statistical Methods
All statistical tests were performed using GraphPad Prism 7.0.
Means were compared using two-way ANOVA followed by the
Bonferroni multiple comparison test. For survival, differences
were evaluated using Kaplan-Meier curves with log-rank test.
Data are represented as mean ± S.E. with statistical significance
values indicated in the figure legends together with the n values
used to calculate the statistics. All in vitro experiments with MM
cells have been repeated at least three times using samples from
the same source as technical replicates. In vivo studies as well as
experiments with primary cells were also repeated at least three
times using different sources as biological replicates.
RESULTS
Transcriptome Analysis and Antigen
Selection
With the goal of designing a universal vaccine that can be used
to target MM as tested in mice, we analyzed expression of
all the mRNA produced by different MM tumors and normal
tissues. Our hypothesis was that antigens highly expressed
in MM tumors can be targeted for vaccination, as long the
expression of those antigens is extremely low in all normal
mouse tissues. mRNA was analyzed in two tumors originating
from two different MM cell lines injected in BALB/c mice,
CRH5, and EOH6. These cells were previously generated by
injecting asbestos or erionite in the same mouse strain (15).
For the normal tissues, we analyzed antigen expression in
lungs and kidneys isolated from naïve BALB/c mice. Selected
antigens had the highest expression in both MM tumors
and the lowest in both normal tissues. Among these, only
antigens that were commonly overexpressed by both MM
tumors were included in the multi-antigen universal vaccine.
Since we analyzed only two normal mouse tissues, we also
considered transcriptome studies performed in other studies
to evaluate the expression of the selected antigens in normal
tissues (17, 18). At the end of this process, we selected the
following seven antigens: KIF20A, KIF2C, MMP9, MNDA,
OLFML2B, TROAP, and ULBP1. The mRNA expression levels
for these antigens in tumor and normal tissues are shown
FIGURE 1 | p-Tvax antigens are overexpressed in MM tumors. Transcriptome
analysis using mRNA-microarrays was performed on two MM mouse tumors
(grown from injected CRH5 or EOH6 cells) and two normal tissues (kidney and
lung). mRNA levels are indicated by Row Z-Score colors in a heat map.
Antigens with the higher mRNA level for both tumors, compared with both
normal tissues, were selected for inclusion in the p-Tvax vaccine. Differences
in mRNA levels between each MM tumor and each normal tissue were
statistically significant for all antigens (p < 0.001).
TABLE 1 | p-Tvax epitopes.
N. Antigen Start
position
Peptide Length
1 KIF20A 860 Ac-SSTDSSPYARILRSRHSPLLK-amide 21
2 KIF2C 356 GDLSGKSQNASKGIYAMASRDVFLLKN-amide 27
3 MMP9 594 RVFFFSGRQMWVYTGKTVLGPRSLDKLGL-amide 29
4 MNDA 298 Ac-NETSSVLEAAPKQMIEVPNCITRN -amide 24
5 OLFML2B 50 DNQENVLSQLLGDYDKVKAVSEGSD-amide 25
6 TROAP 156 Ac-KGGTTQRGQSARSSAYLAPRIPTH-amide 24
7 ULBP1 56 Ac-LNRQPLFVYKDKKCHAIGAHRNSMNATKI-amide 29
Amino acid sequences of each antigen were screened with EpiMatrix to identify epitopes
with potential immune stimulatory properties in BALB/c mice. Putative regulatory T cells
epitopes (Tregitopes), which promote suppression of vaccine-induced T cell responses,
and autoimmune epitopes (autoepitopes) that have potential of inducing autoimmune
reactions were selected against using JanusMatrix algorithm. For each antigen, a peptide
that contained both MHC-I and -II epitopes was synthetized as listed and used for
vaccination, or for detection of antigen-specific immune responses.
in Figure 1. We also tried to evaluate protein expression
of these antigens in CRH5 and EOH6MM tumors with
western blot assays. In these experiments, among the numerous
antibodies tested, only those for OLFML2B, TOAP, and KIF20A
specifically detected the proteins targeted by the universal vaccine
(Supplementary Figure 1).
In silico Epitope Mapping and Peptide
Selection
Each of the antigens selected for vaccination was screened
for MHC-I and MHC-II T cell epitopes using the EpiMatrix
algorithm. Using the JanusMatrix algorithm, we also identified
putative regulatory T cell epitopes (Tregitopes), which can
promote suppression of vaccine-induced T cell responses, as
well as autoimmune epitopes (autoepitopes). For each of
the seven antigens, we selected a sequence that contained
multiple predicted MHC-I and MHC-II restricted T cell
epitopes, and no Tregitopes nor autoepitopes (Table 1). A
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mixture of all these peptides was used as multi-antigen vaccine
named p-Tvax.
p-Tvax Vaccination Induces
Antigen-Specific T Cell Responses
To determine if p-Tvax induces antigen-specific CD4+ and
CD8+ T cells, we vaccinated BALB/c mice and evaluated T cell
responses using intracellular cytokine staining (ICS). Cells from
spleens of immunized mice were re-stimulated with each peptide
listed in Table 1 and production of IFN-γ investigated with flow
cytometry. In these assays, each of the p-Tvax peptides induced
higher levels of IFN-γ+ CD8+ T cells compared to unstimulated
CD8+ T cells, but only peptides 1, 2, 3, and 4 induced significant
numbers of IFN-γ+ CD4+ T cells (Figures 2A,B).
We also confirmed that p-Tvax-induced T cells are able
to recognize the antigen-specific epitopes on the surface of
MM cells and initiate a Granzyme B-based cytolytic response.
For these assays, we pooled the T cells stimulated with
each peptide and evaluated their Granzyme B secretion by
ELISPOT, following incubation with MM cells. Three different
MM cell lines were used as target cells for these analyses.
This included CRH5 and EOH6 cells, which are known to
express the antigens included in p-Tvax, and AB12 cells,
in which antigen expression was unknown at the time of
the vaccine design. In these assays, we used effector T
cells from unvaccinated mice as controls that, along with T
cells from vaccinated mice, were unstimulated or stimulated
with all the p-Tvax peptides. T cells from vaccinated mice
stimulated with the p-Tvax peptides produced high numbers
of Granzyme B spots when co-cultured with all 3MM
cell lines (Figure 2C). Importantly, even though the p-Tvax
design was specific for the antigens expressed in CRH5 and
EOH6MM cells, this vaccine was able to elicit T cells that
also recognized AB12MM cells. This suggests that the antigens
included in p-Tvax represent a group of commonly expressed
proteins across mouse MM tumors. In contrast, Granzyme B
ELISPOT experiments performed using non-tumor mesothelial
cells did not show differences between unstimulated and
stimulated T cells in both vaccinated and control mice (data
not shown).
Vaccination With p-Tvax and Engagement
of the OX40 Receptor Elicits Potent
Anti-tumor Responses in Subcutaneous
and Intraperitoneal Mouse Models of MM
Multi-antigen cancer vaccines such as p-Tvax may serve as an
effective approach to stimulate multiple populations of cancer-
specific T cells, but the activity of these immune cells is hindered
within the tumor microenvironment by several mechanisms,
including the suppressive action by T regulatory cells (Tregs).
Since OX40 agonists have been demonstrated to reduce the
number of Tregs in the tumor microenvironment (10, 19),
we evaluated the combination of p-Tvax with these agonistic
antibodies as a therapeutic approach for MM in animal models.
For the immunization protocol, we chose to administer two
vaccinations with p-Tvax separated by 1 week. CpG adjuvant
injections were performed 2 d before each p-Tvax immunization.
This protocol elicits potent immune responses in mice (20).
To engage the OX40 receptor on T cells, we performed two
injections of the OX86 mAb, with the first dose injected 5 d
prior to the last p-Tvax vaccination, and the second on the
same day as the last p-Tvax injection (Figure 3). This protocol
was chosen to minimize the clearance of the OX86 mAb by
the immune system since these antibodies were developed in a
species different from mice (i.e., rat). In s.c. models of MM, we
used CRH5MM cells and initiated vaccinations when tumors
reached 3–4mm in diameter. In these mice, we observed reduced
tumor growth with p-Tvax alone or in combination with the
OX86 mAb compared to unvaccinated controls or OX86 mAb
alone. Survival analyses revealed that mice vaccinated with p-
Tvax or with p-Tvax and OX86mAb exhibited prolonged median
survival compared with the controls or with OX86 mAb alone
(Figure 4A). Since MM usually develops from mesothelial cells
lining both thoracic and peritoneal cavities, we developed a
clinically relevant MM model to test the therapeutic efficacy of
p-Tvax and OX86 mAbs. For this model, we i.p.injected EOH6
cells previously transduced with a lentiviral vector encoding
the luciferase enzyme, which enabled the localization and
evaluation of tumor dimensions in live mice using an IVIS
imaging system. In these mice, p-Tvax was less efficacious
as indicated by reduced tumor dimensions closer to the end
of the protocol (day 27) and differences over time were not
statistically significant when compared with controls. In contrast,
the OX86 mAb alone exerted statistically significant anti-cancer
activity that delayed tumor growth for the entire protocol.
These results were dramatically improved by the combination
of p-Tvax and OX86 mAb, with mice showing no signs of
tumor at day 20. In these mice, however, tumor cells were
not completely eliminated and became visible with the IVIS
machine the following week. Survival analysis of these mice
showed that vaccination with p-Tvax together with the OX86
mAb resulted in prolonged survival compared with OX86 mAb
alone. The p-Tvax vaccine alone did not lead to increased
survival (Figure 4).
We also evaluated the anti-cancer effects of p-Tvax and the
OX86mAb in mice injected with AB12MM cells. Results showed
that p-Tvax reduced tumor growth, but did not improve survival.
The OX86 mAb alone delayed tumors and improved survival
compared to controls. The combination of p-Tvax plus the OX86
mAb was effective in delaying tumor growth equivalent to the
monotherapy treatments. In survival experiments, p-Tvax in
combination with OX86 mAbs dramatically improved overall
survival, with 20% of vaccinated mice experiencing complete
tumor regression. These results were statistically significant
when compared with controls or each immunotherapy alone
(Supplementary Figure 2). Importantly, no adverse events were
observed for any treatment groups such as acute effects, distress,
or weight loss, and gross tissue examination failed to uncover any
toxicity in the organs (kidney, brain, spleen, liver, and lungs). It
is important to mention that the expression of p-Tvax antigens
was unknown in AB12MM cells when these experiments were
performed, but subsequently confirmed before the publication of
this article (Supplementary Figure 2).
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FIGURE 2 | p-Tvax stimulates antigen-specific IFN-γ secreting T lymphocytes that produce Granzyme B when co-cultured with MM cells. BALB/c mice were
vaccinated with two s.c. injections of p-Tvax peptides at days 2 and 9. CpG 1585 was used as adjuvant and injected at the same site of the p-Tvax peptides 2 days
before vaccination, at days 0 and 7. OX40 agonist mAbs (OX86) were i.p. injected at days 4 and 9. Control mice were left untreated. Five days after the last
vaccination, spleen cells were isolated and enumerated for assays. (A) Intracellular IFN-γ in CD4+ T cells was evaluated by flow cytometric ICS analyses of spleen
cells cultured with or without p-Tvax peptides. Percentage of IFN-γ expressing CD4+ T cells are presented as mean ± S.E. Bottom Panel: Representative data from
flow cytometric analysis of vaccinated and control mice. Lymphocytes were either unstimulated (no peptide = NP) or stimulated with peptide 2. CD4+ T cells were
distinguished using a marker gate in the CD3 vs. CD4 dot plot. (B) IFN-γ in CD8+ T cells was evaluated in spleen cells cultured with or without p-Tvax peptides.
Percentage of IFN-γ expressing CD8+ T cells are presented as mean ± S.E. Bottom Panel: Representative data from flow cytometric analysis of vaccinated and
control mice. Lymphocytes were either not stimulated (NP) or stimulated with peptide 1. CD8+ T cells were distinguished using a marker gate in the CD3 vs. CD8 dot
plot. For A and B, statistical significance between treated and control groups was determined by ANOVA followed by Bonferroni test (*p < 0.05, n = 5). (C) Secretion
of Granzyme B was evaluated by ELISPOT assay. Spleen cells from vaccinated mice (V) or unvaccinated (no vaccine = NV) were activated with p-Tvax peptides in the
presence of 5 IU/ml IL-2 for 6 d (stimulation = S) or incubated with no peptide (no stimulation = NS). Following 4 h of incubation with different MM cells (AB12, CRH5,
EOH6), the number of spot-forming cells per 105 cells was evaluated and results represented as mean ± S.E. Statistical differences between vaccinated mice,
stimulated with peptides (V/S), and the other control conditions were evaluated by ANOVA followed by Bonferroni test (*p < 0.05, n = 3).
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FIGURE 3 | Experimental approach to evaluate p-Tvax and OX40 agonists anti-cancer properties. Two s.c. vaccinations were administered with p-Tvax separated by
1 week. Two days before each p-Tvax immunization, CpG adjuvant injections were performed. To engage the OX40 receptor on T cells, we performed two injections
of the OX86 mAb, with the first dose injected 5 d prior to the last p-Tvax vaccination, and the second on the same day as the last p-Tvax injection. Untreated controls
and mice treated with the different immunotherapies were followed for tumor dimension and survival.
Immunotherapy With p-Tvax Plus the OX86
mAb Induces an Immunostimulatory Tumor
Microenvironment
We next evaluated the effects of the different immunotherapies
in MM models in terms of leukocyte cell populations in tumors
using multicolor flow cytometry. This enabled the simultaneous
identification of several different cell types in one sample,
including CD8+ and CD4+ T cells, and Tregs. In CRH5 tumors,
a higher percentage of CD4+ T helper cells was detected
in p-Tvax vaccinated mice vs. controls, while abundance of
CD8+ T cells and Tregs was not different from controls.
The OX86 mAb increased abundance of CD8+ cytotoxic T
cells, but reduced numbers of CD4+ T cells and Tregs. The
combination of p-Tvax and the OX86 mAb modified the tumor
microenvironment in a manner that led to more optimal anti-
cancer immune conditions as supported by higher abundance of
both CD8+ and CD4+ T cells, and reduced percentages of Tregs
(Figure 5). In EOH6 tumors, we observed similar results with
the only difference found with OX86 mAb that did not reduce
significantly the number of CD4+ Tregs when used as single
treatment (Supplementary Figure 3). To further characterize the
tumor infiltrate, we also measured the expression of PD-1 in
CD4+ and CD8+ T cells, as well as the expression of OX40 in
Tregs. PD-1 expression was significantly reduced in CD4+ T cells
following treatment with both p-Tvax and OX86 mAb, while its
expression did not change in CD8+ T cells. Interestingly, the
expression of OX40 in CD4+ CD25+ Tregs, which represent
their activation status, was reduced following treatment with
either OX86 mAb or with the combination of p-Tvax plus OX86
(Supplementary Figure 4).
DISCUSSION
In this study, we developed a novel immunotherapy combination
comprised of a multi-antigen MM-specific vaccine combined
with an OX40 agonist mAb leading to the reduction of tumor
growth. The vaccine design started with the analysis of the MM
tumor transcriptome performed in neoplastic tissues generated
from two different MM cell lines, CRH5 and EOH6. Antigens
that were highly expressed in both cells were chosen as candidates
for inclusion in our vaccine. It has been established that the
high expression of certain proteins within tumor cells leads to
increased antigenic processing and presentation in the context
of MHC-I and -II (21, 22). These fragments, referred to as
tumor epitopes, represent targets for T cells that can specifically
recognize the tumor cell for immune-mediated elimination. To
minimize off-target effects that could lead to the development
of autoimmunity, it is important to choose antigens that are
not expressed or minimally detectable in normal tissues (23).
In this regard, we also evaluated antigen expression in normal
tissues in our laboratory as well as expression data from the
literature (17, 18). This led to the selection of seven antigens
found to be overexpressed in both mouse MM tumor lines under
investigation and that were nearly absent in all other mouse
normal tissues: KIF20A, KIF2C, MMP9, MNDA, OLFML2B,
TROAP, and ULBP1. It is important to mention that we also
tried to confirm the protein expression of these antigens in MM
tumors using western blot. In these experiments, we evaluated
several antibodies and specifically detected high levels of KIF20A,
OLFML2B, and TROAP in MM tumors. Regarding the other
proteins, the antibodies tested could not specifically recognize
the antigens that we included in the vaccine. These negative
results may be due to the rapid degradation of the proteins,
or to their improper folding in tumor cells. However, it has
been demonstrated that pre-maturely truncated or abnormally
folded proteins are exported to the cytosol, processed by the
proteasome and resultant peptides loaded on MHC-I and -II to
trigger specific immune responses (24–26).
For each of the seven chosen antigen, we designed a peptide
that contained both MHC-I and -II epitopes with the capacity to
stimulate both CD8+ and CD4+ T cells. Epitope screening was
performed using the iVAX platform which contains advanced
in silico tools designed to identify highly immunogenic epitopes
with EpiMatrix, while selecting against epitopes that may
stimulate Treg or autoimmune responses with JanusMatrix. By
including these optimized epitopes in our vaccine, we reduced the
potential for suppressive or off-target effects. The development
of these innovative in silico tools will increasingly provide the
capacity for safe and effective vaccines (5–7).
Mice vaccinated with the multi-antigen vaccine (p-Tvax),
mounted antigen-specific immune responses that involved both
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FIGURE 4 | Combination of p-Tvax vaccine and OX40 agonists delays tumor growth and improves survival in subcutaneous and intraperitoneal mouse models of
MM. (A) BALB/c mice were injected s.c. with 5 × 104 CRH5MM cells, or i.p. with 2 × 105 EOH6MM cells expressing luciferase. Seven and 14 d after tumor
injection, mice were vaccinated with a s.c. injection of p-Tvax peptides. CpG adjuvant was injected at days 5 and 12, while 200 µg of OX86 was injected at day 9 and
14. Tumor volumes are showed on the left and animal survivals on the right for mice injected with CRH5 (Top) and EOH6 (Bottom). Tumor volumes were measured
weekly with a caliper for s.c. tumors. I.p. MM dimensions were assessed by measuring luciferase activity with IVIS imaging following injection with luciferin substrate.
Statistical significance between unvaccinated controls and single treatment (*) as well as between single and combination treatments (**), was determined by ANOVA
followed by Bonferroni test (*p < 0.05, n = 5). For survival, mice were followed until s.c. CRH5 tumors reached volumes of 300 mm3 and were then sacrificed. In i.p.
models with EOH6MM cells, survival was assessed by euthanizing mice at first sign of morbidity. Log-rank analysis was used to determine significance between
control and single treatment (*), and between single and combination treatments (**) (p < 0.05, n = 5). (B) Representative images from IVIS tumor dimension analysis
of mice carrying EOH6 tumors, vaccinated with the different immunotherapies.
CD8+ and CD4+ T cells. These data were obtained using
intracellular staining of peptide-pulsed T cells followed by flow
cytometry analysis. A different approach to confirm these data,
and to provide more quantitative results, would have been the
characterization of antigen-specific T cells using MHC tetramers.
Unfortunately, these reagents are not commercially available for
the epitopes involved in this study. T cells from p-Tvax vaccinated
mice were also demonstrated to recognize and attack tumor
cells by secreting Granzyme B in ELISPOT assays performed
with different MM cell lines. Among these MM cells recognized
by vaccine-induced T cells was the AB12 cell line. AB12 cells
were not included in the initial transcriptomic analyses for
antigen selection, and in this manner served as an important
comparison group in our studies. These data demonstrate that,
by selecting multiple antigens commonly expressed in several
MM cases, it is possible to construct an off-the-shelf vaccine
that may be efficacious for a wide variety of MM. This approach
to cancer vaccine development may complement or be used in
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FIGURE 5 | p-Tvax in combination with OX40 agonists induce CD8+ and CD4+ T cell tumor infiltration while reducing T regulatory cells. CRH5 tumors from controls
or from mice treated with p-Tvax, OX86 mAbs, or with a combination of the two, were collected and enzyme-digested. Staining was performed using anti-mouse
CD3, CD8, CD4, CD25, and FoxP3 antibodies with live cells distinguished from debris using LIVE/DEAD® cell viability dye. (A) Percentage of CD8+ T cells in CRH5
tumors from treated and control mice. Results represent mean ± S.E. with means of each group compared using ANOVA followed by Bonferroni test (*p < 0.05,
n = 5, vs. Control). Data for CD4+ T cells and Tregs cells are showed, respectively in (B,C). (D) Representative data from flow cytometric analysis of CRH5 tumors in
treated and control mice using CD25 and FoxP3 markers for Tregs, including Tregs that were previously gated in the CD3 vs. CD4 dot plot.
place of personalized cancer vaccine approaches. In addition, off-
the-shelf cancer vaccines bring the possibility of prophylactic
immunization of individuals, which cannot be achieved with
therapeutic personalized vaccines. Personalized immunizations
are considerably more expensive than off-the-shelf vaccines due
to of the cost of peptide synthesis (small vs. large production
under GMP conditions). In addition, personalized vaccine
epitopes tailored for each cancer patient’s mutanome requiring
sophisticated techniques such as whole-exome sequencing, RNA
sequencing, and in silico immunogenicity prediction algorithms
that are not as yet widely available. The safety profile of “off the
shelf ” vaccines such as the one proposed here can be ascertained
well in advance of treatment, whereas the e safety profile of
personalized anti-cancer vaccines remains to be fully evaluated.
For example, a recent study showing that the number of somatic
mutations in normal cells in cancer-related genes may be several
times higher than in the cancer counterparts (27). Alternatively,
vaccines such as the one described in this research study could be
used in conjunction with personalized vaccines, to augment the
number of epitopes to which the patients may respond.
In mouse models, p-Tvax as a stand-alone treatment showed
limited efficacy in delaying tumor growth or in improving
survival in mice carrying certain MM tumors. This was an
expected outcome given the likelihood of immune suppression
within the tumor environment. This is why efficacy of cancer
vaccine can be enhanced by the inclusion of immune stimulatory
Abs such as the OX40 agonist we chose for our study. In fact,
the combination therapy using p-Tvax plus the OX40 agonist
showed both decreased tumor volumes and increased survival
for all three MM mouse models. Interestingly, the OX40 agonist
alone was not effective in one animal model carrying CRH5MM
cells when used as a single agent. This is consistent with data
obtained in clinical trials involving such immune checkpoint
mAbs, in which clinical responses are often limited to a subset
of patients (28, 29).
Analyses of tumor tissues in mice treated with the different
immunotherapies produced results that may be best explained
when considering the combination treatment as a sum of all
the benefits induced by each therapeutic approach, namely,
the combined increase in CD4+ T cells induced by p-Tvax
and the increase in CD8+ T cells induced by OX40 agonists.
Further analysis of the tumor infiltrate also showed that the
combination of p-Tvax and OX40 agonists produced other effects
that may favor tumor clearance such as the reduced expression
of the T cell exhaustion marker PD-1 in CD4+ T cells and
the decrease in number of Tregs. It is important to point out
that mice treated with the combination of p-Tvax and OX40
agonists also showed reduced expression of OX40 in intra-
tumor Tregs, which indicates a lower regulatory activity of these
cells and a more favorable prognosis (10, 30, 31). Our data
collectively suggest that this combination of immunotherapies
could be an attractive therapeutic strategy for MM patients.
Also, considering that humanized OX40 agonists have already
been developed and successfully passed the phase I clinical trials
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(13), this immunotherapeutic mAb approach may serve as an
effective adjuvant to include along with cancer vaccines. We have
demonstrated proof-of-concept supporting p-Tvax in human
immunization, in which target antigens can be chosen from
transcriptome studies performed in MM patients (32, 33).This
may provide the framework for a new approach to combine this
broadly acting vaccine with immunotherapy and/or personalized
cancer vaccines, for treating not only MM, but other types of
cancers as well.
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